ALK‑G1269A mutation in epithelioid inflammatory myofibroblastic sarcoma after progression on crizotinib: A case report

Xu,Xiaojing; Li,Hong; Peng,Ke; Yu,Yiyi; Chen,Lingli; Fang,Yong; Sun,Yihong; Hou,Yingyong; Liu,Tianshu

doi:10.3892/ol.2018.9865

ALK‑G1269A mutation in epithelioid inflammatory myofibroblastic sarcoma after progression on crizotinib: A case report

Authors:
- Xiaojing Xu
- Hong Li
- Ke Peng
- Yiyi Yu
- Lingli Chen
- Yong Fang
- Yihong Sun
- Yingyong Hou
- Tianshu Liu
View Affiliations

Affiliations: Department of Oncology, Zhongshan Hospital, Fudan University, Shanghai 200032, P.R. China, Department of Oncology, Jiahui International Hospital, Shanghai 200032, P.R. China, Department of Pathology, Zhongshan Hospital, Fudan University, Shanghai 200032, P.R. China, Department of General Surgery, Zhongshan Hospital, Fudan University, Shanghai 200032, P.R. China
Published online on: December 21, 2018 https://doi.org/10.3892/ol.2018.9865
Pages: 2370-2376
Copyright: © Xu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Epithelioid inflammatory myofibroblastic sarcoma (EIMS), a specific subtype of inflammatory myofibroblastic tumors (IMT), is a relatively rare malignant mesenchymal tumor with clinical features of positive anaplastic lymphoma kinase (ALK), high invasiveness, treatment resistance and poor prognosis. Therefore, ALK inhibitors represent specific effective drugs for patients with this type of tumor. However, acquired resistance remains inevitable without a clear mechanism of action and therapeutic strategy to counteract this. Herein, a chromosomal ALK‑G1269A mutation was identified using next‑generation sequencing (NGS) and the mutation was confirmed by Sanger sequencing in a patient with crizotinib‑resistant EIMS who benefited from treatment with the second‑generation ALK inhibitor AP26113. To the best of our knowledge, a few rare cases of crizotinib‑resistance in IMTs have been reported, and there are no reported cases in EIMS. In this article, we present the case of a patient with a secondary mutation of ALK‑G1269A in EIMS, and suggest that AP26113 (Brigatinib) may represent an ideal treatment for these patients.

View Figures

View References

1	Mariño-Enríquez A, Wang WL, Roy A, Lopez-Terrada D, Lazar AJ, Fletcher CD, Coffin CM and Hornick JL: Epithelioid inflammatory myofibroblastic sarcoma: An aggressive intra-abdominal variant of inflammatory myofibroblastic tumor with nuclear membrane or perinuclear ALK. Am J Surg Pathol. 35:135–144. 2011. View Article : Google Scholar : PubMed/NCBI
2	Yu L, Liu J, Lao IW, Luo Z and Wang J: Epithelioid inflammatory myofibroblastic sarcoma: A clinicopathological, immunohistochemical and molecular cytogenetic analysis of five additional cases and review of the literature. Diagn Pathol. 11:672016. View Article : Google Scholar : PubMed/NCBI
3	Liu Q, Kan Y, Zhao Y, He H and Kong L: Epithelioid inflammatory myofibroblastic sarcoma treated with ALK inhibitor: A case report and review of literature. Int J Clin Exp Pathol. 8:15328–15332. 2015.PubMed/NCBI
4	Kruczynski A, Delsol G, Laurent C, Brousset P and Lamant L: Anaplastic lymphoma kinase as a therapeutic target. Expert Opin Ther Targets. 16:1127–1138. 2012. View Article : Google Scholar : PubMed/NCBI
5	Kimbara S, Takeda K, Fukushima H, Inoue T, Okada H, Shibata Y, Katsushima U, Tsuya A, Tokunaga S, Daga H, et al: A case report of epithelioid inflammatory myofibroblastic sarcoma with RANBP2-ALK fusion gene treated with the ALK inhibitor, crizotinib. Jpn J Clin Oncol. 44:868–871. 2014. View Article : Google Scholar : PubMed/NCBI
6	Heigener DF and Reck M: Crizotinib. Recent Results Cancer Res. 211:57–65. 2018. View Article : Google Scholar : PubMed/NCBI
7	Voena C and Chiarle R: The battle against ALK resistance: Successes and setbacks. Expert Opin Investig Drugs. 21:1751–1754. 2012. View Article : Google Scholar : PubMed/NCBI
8	Su D, Zhang D, Chen K, Lu J, Wu J, Cao X, Ying L, Jin Q, Ye Y, Xie Z, et al: High performance of targeted next generation sequencing on variance detection in clinical tumor specimens in comparison with current conventional methods. J Exp Clin Cancer Res. 36:1212017. View Article : Google Scholar : PubMed/NCBI
9	Fang H, Langstraat CL, Visscher DW, Folpe AL and Schoolmeester JK: Epithelioid inflammatory myofibroblastic sarcoma of the ovary with RANB2-ALK fusion: Report of a case. Int J Gynecol Pathol. 37:468–472. 2018.PubMed/NCBI
10	Lee JC, Li CF, Huang HY, Zhu MJ, Mariño-Enríquez A, Lee CT, Ou WB, Hornick JL and Fletcher JA: ALK oncoproteins in atypical inflammatory myofibroblastic tumours: Novel RRBP1-ALK fusions in epithelioid inflammatory myofibroblastic sarcoma. J Pathol. 241:316–323. 2017. View Article : Google Scholar : PubMed/NCBI
11	Fang N, Yang QJ, Deng YT, Feng X, Xia HS, Zhang YG, Wang MW, Wu D, Zhou H and Guo F: Epithelioid inflammatory myofibroblastic sarcoma of small bowel mesentery: Report of a case. Zhonghua Bing Li Xue Za Zhi. 46:201–202. 2017.(In Chinese). PubMed/NCBI
12	Mansfield AS, Murphy SJ, Harris FR, Robinson SI, Marks RS, Johnson SH, Smadbeck JB, Halling GC, Yi ES, Wigle D, et al: Chromoplectic TPM3-ALK rearrangement in a patient with inflammatory myofibroblastic tumor who responded to ceritinib after progression on crizotinib. Ann Oncol. 27:2111–2117. 2016. View Article : Google Scholar : PubMed/NCBI
13	Michels SYF, Scheel AH, Wündisch T, Heuckmann JM, Menon R, Puesken M, Kobe C, Pasternack H, Heydt C, Scheffler M, et al: ALKG1269A mutation as a potential mechanism of acquired resistance to crizotinib in an ALK-rearranged inflammatory myofibroblastic tumor. NPJ Precis Oncol. 1:42017. View Article : Google Scholar : PubMed/NCBI
14	Sasaki T, Okuda K, Zheng W, Butrynski J, Capelletti M, Wang L, Gray NS, Wilner K, Christensen JG, Demetri G, et al: The neuroblastoma-associated F1174L ALK mutation causes resistance to an ALK kinase inhibitor in ALK-translocated cancers. Cancer Res. 70:10038–10043. 2010. View Article : Google Scholar : PubMed/NCBI
15	Nishio M, Murakami H, Horiike A, Takahashi T, Hirai F, Suenaga N, Tajima T, Tokushige K, Ishii M, Boral A, et al: Phase I study of ceritinib (ldk378) in Japanese patients with Advanced, Anaplastic lymphoma kinase-rearranged non-small-cell lung cancer or other tumors. J Thorac Oncol. 10:1058–1066. 2015. View Article : Google Scholar : PubMed/NCBI
16	Katayama R, Lovly CM and Shaw AT: Therapeutic targeting of anaplastic lymphoma kinase in lung cancer: A paradigm for precision cancer medicine. Clin Cancer Res. 21:2227–2235. 2015. View Article : Google Scholar : PubMed/NCBI
17	Huang WS, Liu S, Zou D, Thomas M, Wang Y, Zhou T, Romero J, Kohlmann A, Li F, Qi J, et al: Discovery of brigatinib (AP26113), a phosphine oxide-containing, potent, orally active inhibitor of anaplastic lymphoma kinase. J Med Chem. 59:4948–4964. 2016. View Article : Google Scholar : PubMed/NCBI